Advertisement

Topics

Nkarta licenses IP from National Univ. of Singapore, St. Jude Children's

15:40 EDT 22 Jun 2018 | Elsevier Business Intelligence

Nkarta Therapeutics Inc. licensed exclusive global rights to natural killer (NK) cell engineering technology jointly owned by...

Original Article: Nkarta licenses IP from National Univ. of Singapore, St. Jude Children's

NEXT ARTICLE

More From BioPortfolio on "Nkarta licenses IP from National Univ. of Singapore, St. Jude Children's"

Advertisement
Quick Search
Advertisement
Advertisement